Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | +0.33% | -2.86% | -4.97% |
Apr. 30 | B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
Apr. 29 | HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
Financials (USD)
Sales 2024 * | 12.81M | Sales 2025 * | 43.7M | Capitalization | 217M |
---|---|---|---|---|---|
Net income 2024 * | -54M | Net income 2025 * | -23M | EV / Sales 2024 * | 16.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.96 x |
P/E ratio 2024 * |
-4.11
x | P/E ratio 2025 * |
-10.5
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.03% |
Latest transcript on Ovid Therapeutics Inc.
1 day | +0.33% | ||
1 week | -2.86% | ||
Current month | +0.33% | ||
1 month | -0.97% | ||
3 months | -20.93% | ||
6 months | -14.76% | ||
Current year | -4.97% |
Managers | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Jeffrey Rona
DFI | Director of Finance/CFO | 55 | 18-12-31 |
Zhong Zhong
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Duncan
BRD | Director/Board Member | 59 | 17-06-13 |
Bart Friedman
BRD | Director/Board Member | 79 | 15-11-22 |
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +1.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 3.06 | +0.33% | 222,034 |
24-04-30 | 3.05 | -8.68% | 240,074 |
24-04-29 | 3.34 | +7.74% | 311,343 |
24-04-26 | 3.1 | +3.68% | 80,529 |
24-04-25 | 2.99 | -5.08% | 112,117 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.97% | 216M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- OVID Stock